For scoring PD-L1 positive tumor cells for NSCLC, various studies report a low inter-observer agreement [1] for pathologists, which gives rise to the concern, that the decision of immunotherapy treatment eligibility depends on the lab the sample is evaluated in. Visiopharm’s PD-L1 (NSCLC) algorithm reliably detects invasive tissue and quantifies the positive tumor cells. In the integrated workflow, the analysis is triggered and done fully-automated, delivering the results for the pathologist’s review once ready.
Our clinical validation study with three European sites directly compared manual assessments (as ground truth) with the APP’s stand-alone analysis and pathologist’s APP-assisted interpretations.
[1] Troncone G, Gridelli C; doi: 10.21037/tlcr.2017.10.05
